CDEX, Inc. Delivers First Production ValiMed Medication Validation System
ROCKVILLE, MD.–April 25, 2006– CDEX, Inc. (CEXI.OB) announced today that it has delivered the first ValiMed Medication Validation System production units in the initial installment of the systems purchased by Baxa Corporation (www.baxa.com) under their reseller agreement with CDEX (www.cdex-inc.com). The ValiMed Medication Validation System is designed to verify narcotic disposal and validate pharmaceuticals, including concentration and diluents, in patient medications. The first production units were prepared to verify 33 medications (nine narcotics and 24 medications) for both doses and diluents.
The information obtained from CDEX beta partners has permitted the company to incorporate significant changes to the system from the original design. The current configuration can validate narcotic disposal of such narcotics as Fentanyl at 50 mcg/ml and differentiate patient care drugs such as Epinephrine at 0.005 mg/ml and Epinephrine at 0.01 mg/ml.
“The delivery of the first ValiMed production units marks a significant milestone in the CDEX growth strategy. The shipment of the ValiMed systems has positioned the company to focus on overall market penetration for the ValiMed product. Our proven production capabilities coupled with our recent TUV certification has opened significant opportunities for us both in the U.S. and overseas,” stated Jim Griffin, President and CEO of CDEX, Inc.
The ValiMed medication library currently consists of 33 narcotics and patient care medications, and is scheduled to be expanded to more than 140 medications, doses and diluents, by the end of the year. ValiMed’s improved capabilities and an expanding medication library will ensure that the system becomes an essential tool for improving patient safety.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Media Contact:
Brad Wills
Wills & Associates, Inc.
t. 301-767-1919
m. 301-346-7398
bwills@wills-pr.com
